CLL Pharma
Records under this name other than patents CLL Pharma holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 6 of 6 · Back to CLL Pharma
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,192,654 | Use of the PAT nanopeptide in treating and preventing neurodegenerative diseases Lapsed on the fee record Ended Nov 24, 2023 · From the USPTO record | Lapsed on the fee record | Ended Nov 24, 2023 | From the USPTO record |
| US 9,427,455 | Use of the pat nanopeptide in the treatment of autoimmune diseases Lapsed on the fee record Ended Aug 30, 2020 · From the USPTO record | Lapsed on the fee record | Ended Aug 30, 2020 | From the USPTO record |
| US 9,029,390 | Oral composition containing an antiplatelet agent of the thienopyridine family in the form of free base Lapsed on the fee record Ended May 12, 2019 · From the USPTO record | Lapsed on the fee record | Ended May 12, 2019 | From the USPTO record |
| US 7,365,055 | Derivatives of morphine-6-glucuronide, pharmaceutical compositions containing them, their preparation method and their uses Formerly held Lapsed on the fee record Ended Apr 29, 2012 · From the USPTO record | Lapsed on the fee record | Ended Apr 29, 2012 | From the USPTO record |
| US 6,669,957 | Galenic formulations fast disintegrating in the mouth and method for preparing same Lapsed on the fee record Ended Dec 30, 2011 · From the USPTO record | Lapsed on the fee record | Ended Dec 30, 2011 | From the USPTO record |
| US 5,827,536 | Pharmaceutical dosage formulations of fenofibrate and their applications Term ended Term ended no later than Oct 27, 2018 · Low confidence | Term ended | Term ended no later than Oct 27, 2018 | Low confidence |